



US010376470B2

(12) **United States Patent**  
**Dias et al.**

(10) **Patent No.:** **US 10,376,470 B2**  
(45) **Date of Patent:** **\*Aug. 13, 2019**

(54) **ORAL TABLET FORMULATION  
CONSISTING OF FIXED COMBINATION OF  
ROSUVASTATIN AND EZETIMIBE FOR  
TREATMENT OF HYPERLIPIDEMIA AND  
CARDIOVASCULAR DISEASES**

(71) Applicant: **Althera Life Sciences, LLC**,  
Morristown, NJ (US)

(72) Inventors: **Marie Charmaine Dias**, Morristown,  
NJ (US); **Chandir Ramani**, Brpton  
(CA)

(73) Assignee: **Althera Life Sciences, LLC**,  
Morristown, NJ (US)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-  
claimer.

(21) Appl. No.: **15/687,492**

(22) Filed: **Aug. 27, 2017**

(65) **Prior Publication Data**

US 2017/0354604 A1 Dec. 14, 2017

**Related U.S. Application Data**

(63) Continuation-in-part of application No. 14/350,905,  
filed as application No. PCT/US2013/039018 on May  
1, 2013, now Pat. No. 9,763,885.

(60) Provisional application No. 61/641,013, filed on May  
1, 2012.

(51) **Int. Cl.**

**A61K 9/00** (2006.01)  
**A61K 31/00** (2006.01)  
**A61K 9/24** (2006.01)  
**A61K 31/505** (2006.01)  
**A61K 31/397** (2006.01)  
**A61K 9/20** (2006.01)  
**A61K 9/28** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 9/209** (2013.01); **A61K 9/0053**  
(2013.01); **A61K 9/2009** (2013.01); **A61K**  
**9/2013** (2013.01); **A61K 9/2018** (2013.01);  
**A61K 9/2027** (2013.01); **A61K 9/2054**  
(2013.01); **A61K 9/2059** (2013.01); **A61K**  
**9/2095** (2013.01); **A61K 9/2893** (2013.01);  
**A61K 31/397** (2013.01); **A61K 31/505**  
(2013.01)

(58) **Field of Classification Search**

CPC ..... **A61K 2300/00**; **A61K 31/397**; **A61K**  
**31/505**; **A61K 9/209**; **A61K 9/0053**;  
**A61K 9/2009**; **A61K 9/2013**; **A61K**  
**9/2018**; **A61K 9/2027**; **A61K 9/2054**;  
**A61K 9/2059**; **A61K 9/2095**; **A61K**  
**9/2893**; **A61K 9/2086**

See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

2007/0087050 A1\* 4/2007 Jansen ..... **A61K 9/0056**  
424/464  
2008/0033030 A1\* 2/2008 Capua ..... **A61K 9/2027**  
514/419  
2010/0204195 A1\* 8/2010 Lulla ..... **A61K 9/209**  
514/210.02  
2010/0247645 A1\* 9/2010 Curdy ..... **A61K 31/165**  
424/468  
2011/0262497 A1 10/2011 Injac et al.  
2013/0310420 A1\* 11/2013 Hsiao ..... **A61K 47/02**  
514/311  
2015/0164809 A1\* 6/2015 Nishida ..... **A61K 31/47**  
514/311

**FOREIGN PATENT DOCUMENTS**

EP 2233133 A1\* 9/2010 ..... **A61K 9/2853**  
WO WO-2009024889 A2\* 2/2009 ..... **A61K 31/366**  
WO 2010021608 A1 2/2010  
WO 2011019326 A2 2/2011  
WO 2011139256 A2 11/2011  
WO 2012064307 A1 5/2012

**OTHER PUBLICATIONS**

European Patent Office, Communication pursuant to Article 94(3)  
EPC, dated Apr. 6, 2018 in EP patent application No. 13785009.5.

\* cited by examiner

*Primary Examiner* — Robert A Wax

*Assistant Examiner* — Olga V Tcherkasskaya

(74) *Attorney, Agent, or Firm* — Berggren LLP

(57) **ABSTRACT**

Solid dosage formulations containing a combination of  
rosuvastatin and ezetimibe, as well as methods of making  
such solid dosage forms and method of treating patients with  
fixed combination solid dosage forms of rosuvastatin and  
ezetimibe are provided here.

**7 Claims, 1 Drawing Sheet**